Sleep apnea as a comorbidity in obese psoriasis patients: A cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role?

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 7, 2013, Pages 820-826

  Papadavid, E ^a   Vlami, K ^a   Dalamaga, M ^a   Giatrakou, S ^a   Theodoropoulos, K ^a   Gyftopoulos, S ^a   Stavrianeas, N ^a   Papiris, S ^a   Rigopoulos, D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

ADULT; APNEA HYPOPNEA INDEX; ARTHRITIS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SLEEP DISORDERED BREATHING; SLEEP QUALITY; SMOKING; SNORING; WAIST HIP RATIO;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PSORIASIS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84879076070     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04580.x     Document Type: Article

References (50)

1. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case control study. J Invest Dermatol 2005; 125: 61-67.
2. Sakai R, Matsui S, Fukushima M, et al. Prognostic factor analysis for plaque psoriasis. Dermatology 2005; 211: 103-106.
3. Love TJ, Qureshi AA, Karison EW, et al. Prevalence of the metabolic syndrome in psoriasis: results form the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-424.
4. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital base-case-control study. Br J Dermatol 2007; 157: 68-73.
5. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655.
6. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1533.
7. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB,. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-773.
8. Bonifati C, Carducci M, Cordiali FeiP, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-387.
9. Shirai K,. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004; 20: 295-304.
10. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
11. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
12. Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-357.
13. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
14. Mehta NN, Asfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010; 31: 1000-1006.
15. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
16. Kaye JA, Li L, Jick SS,. Incidence of risk factors for myocardial infraction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
17. Kim N, Thrash B, Menter A,. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-15.
18. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
19. Wu JJ, Channual JC, Dann F,. Association of systemic psoriasis therapies and incidence of myocardial infarction. Br J Dermatol 2012; 166: 232. (in press).
20. Gowda S, Goldblum OM, McCall WV, Feldman SR,. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 2010; 63: 114-123.
21. Shepard JW Jr,. Hypertension, cardiac arrhythmias, myocardial infraction and stroke in relation to obstructive sleep apnea. Clin Chest Med 1992; 13: 437-458.
22. Buslau M, Benotmane K,. Cardiovascular complication of psoriasis: does obstructive sleep apnea play a role? Acta Dermatol Venerol 1999; 79: 234.
23. Yang XQ, You L, Zhang-Rui J,. Study of sleep quality in patients with psoriasis. Institute of Aviation Medicine. J Invest Dermatol 2007; 127: 1809.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
25. Johns MW,. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
26. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk categories. Circulation 1998; 97: 1837-4.
27. Gisondi P, Farina S, Giordano MV, Girolomoni G,. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754-1757.
28. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research: the report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667-689.
29. Iber C, Ancoli-Israel S, Stuart Quan M,. The American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. American Academy of Sleep Medicine, Westchester, IL, 2007.
30. Wilcox I, Mc Namara SG, Collins FL, et al. Syndrome Z the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 53 (Suppl. 3): S25-S28.
31. Rosa DJF, Machado RF, Matias FAT, et al. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 348-353.
32. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al. A prospective case controlled study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164: 26-32.
33. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I,. Obstructive sleep apnea is independently associated with the metabolic syndrome but not insulin state. Cardiovasc Diabetol 2006; 5: 22.
34. Punjabi. The epidemiology of obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-143.
35. Lam JC, Mak JC, Ip MS,. Obesity, obstructive sleep apnea and metabolic syndrome. Respirology 2012; 17: 223-236.
36. Bonsignore MR, McNicholas WT, Montserrat JM, Eckel J,. The adipose tissue in obesity and obstructive sleep apnea. Eur Respir J 2012; 39: 746-767.
37. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811-817.
38. Monahan K, Redline S,. Role of obstructive sleep apnea in cardiovascular disease. Curr Opin Cardiol 2011; 26: 541-547.
39. Parish JM,. Metabolic syndrome, obstructive sleep apnea, and risk of cardiovascular disease. Sleep Breath 2011; [Epub ahead of print].
40. Armstrong AW, Lin SW, Chambers CJ,. Psoriasis and hypertension severity: results from a case-control study. PLoS ONE 2011; 29: 6.
41. Marin JM, Carrizo SJ, Vicente E, Agusti AG,. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 25: 365.
42. Strobel RJ, Rosen RC,. Obesity and weight loss in obstructive sleep: apnea a critical review. Sleep 1996; 19: 104-115.
43. Johansson K, Neovius M, Lagerros YT, et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnea in obese men: a randomised controlled trial. BMJ 2009; 339: b4609.
44. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
45. Ahlehoff O, Gislason GH, Charlot M,. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide study. J Inter Med 2011; 270: 147-157.
46. Wakkee M, Herings RM, Nijsten T,. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
47. Stern RS,. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
48. Stern RS, Huibregtse A,. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011; 131: 1159-1166.
49. Gelfand JM, Mehta NN, Langan SM,. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011; 131: 1007-1010.
50. Yang YW, Keller JJ, Lin HC,. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-1043.